Guinea vs Singapore: Access to anti-retroviral drugs, female
Guinea
83.0%
in 2024
Singapore
84.0%
in 2023
Guinea rank
53rd
Singapore rank
50th
Access to anti-retroviral drugs, female over time
- Guinea
- Singapore
How they compare
Singapore currently reports 84.0% against 83.0% in Guinea, a difference of 1.0%.
Across all 24 years both countries report, Singapore has been ahead every year.
Guinea ranks 53rd and Singapore ranks 50th of 141 countries.
Singapore has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Guinea | Singapore | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 3.7% | 19.9% | 16.2% | Singapore |
| 2010s | 32.7% | 59.6% | 26.9% | Singapore |
| 2020s | 67.0% | 80.8% | 13.8% | Singapore |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Guinea or Singapore?
- Singapore, at 84.0% against 83.0% in Guinea as of 2023.
- What is the difference in access to anti-retroviral drugs, female between Guinea and Singapore?
- 1.0%, with Singapore ahead.
- How many years of comparable data are there for Guinea and Singapore?
- 24 years are reported by both, from 2000 to 2023.
- How do Guinea and Singapore rank globally for access to anti-retroviral drugs, female?
- Guinea ranks 53rd and Singapore ranks 50th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.